Tosca Melissa 4

4 · KIORA PHARMACEUTICALS INC · Filed Mar 10, 2026

AI-generated summary of this filing

Updated Mar 11, 2026

Kiora (KPRX) CFO Melissa Tosca Receives Equity Award

What Happened

Melissa Tosca, Chief Financial Officer of Kiora Pharmaceuticals (KPRX), received equity awards on 2026-03-06: 6,533 restricted shares (award) and an option/derivative covering 13,067 shares. Both grants show $0.00 per share at grant (no cash paid at grant).

Key Details

Transaction date: March 6, 2026. Filing date (Form 4): March 10, 2026 (filed within applicable reporting window for a March 6 transaction).
Price: $0.00 per share reported for both the restricted stock and the derivative grant.
Shares acquired: 6,533 restricted shares (direct award); 13,067-share option/derivative.
Shares owned after transaction: Not specified in the provided filing details.
Footnotes / vesting:
- F1: Restricted stock vests one-third on each of April 1, 2027; April 1, 2028; and April 1, 2029, subject to continuous service.
- F2: Option becomes exercisable one-third on April 1, 2027; remaining balance vests monthly on the first day of each month over the following two years, subject to continuous service.
Transaction code: A = Award/Grant.

Context

These are time-based equity grants, not open-market purchases or sales. The option/derivative is a future right to buy shares per the vesting schedule; there is no immediate exercise or sale reported. Such awards are common as compensation and align pay with future service and company performance; they do not by themselves indicate insider buying or selling intent.

Form 4

Period: 2026-03-06

CFO

Transactions

Award
Common Stock
[F1]
2026-03-06+6,533→ 27,904 total
Award
Stock Option (right to buy)
[F2]
2026-03-06+13,067→ 13,067 total
Exercise: $1.98From: 2027-04-01Exp: 2036-04-01→ Common Stock (13,067 underlying)

Footnotes (2)

[F1]Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1 , 2027, April 1 , 2028 and April 1 , 2029, subject to the reporting person's continuous service through each such vesting date.
[F2]The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2027, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

Signature

/s/ Melissa Tosca|2026-03-10

1 file